CL2008001612A1 - 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. - Google Patents
5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.Info
- Publication number
- CL2008001612A1 CL2008001612A1 CL2008001612A CL2008001612A CL2008001612A1 CL 2008001612 A1 CL2008001612 A1 CL 2008001612A1 CL 2008001612 A CL2008001612 A CL 2008001612A CL 2008001612 A CL2008001612 A CL 2008001612A CL 2008001612 A1 CL2008001612 A1 CL 2008001612A1
- Authority
- CL
- Chile
- Prior art keywords
- thiadiazolidin
- pharmaceutical composition
- naphthalen
- dioxo
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos derivados de [1,2,5]-tiadiazolidin-3-ona; composición farmacéutica; y uso en el tratamiento de enfermedades tales como resistencia a la insulina, diabetes tipo 2, dislipidemia, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94176807P | 2007-06-04 | 2007-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001612A1 true CL2008001612A1 (es) | 2009-05-15 |
Family
ID=39720401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001612A CL2008001612A1 (es) | 2007-06-04 | 2008-06-03 | 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100197744A1 (es) |
EP (1) | EP2155704A1 (es) |
JP (1) | JP2010529075A (es) |
CN (1) | CN101687828A (es) |
AR (1) | AR066820A1 (es) |
CL (1) | CL2008001612A1 (es) |
PE (1) | PE20090762A1 (es) |
TW (1) | TW200911769A (es) |
WO (1) | WO2008148744A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1963294B1 (en) * | 2005-12-08 | 2012-10-10 | Novartis AG | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
JP2009518421A (ja) * | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | 1,1,3−トリオキソ−1,2,5−チアジアゾリジンおよびPTPase阻害剤としてのそれらの使用 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN105213386A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213382A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287532A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232545A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232547A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232544A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105520943A (zh) * | 2015-11-11 | 2016-04-27 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105434434A (zh) * | 2015-11-11 | 2016-03-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213379A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193797A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105412095A (zh) * | 2015-11-11 | 2016-03-23 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105250276A (zh) * | 2015-11-11 | 2016-01-20 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213385A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193800A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213381A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287535A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105434433A (zh) * | 2015-11-11 | 2016-03-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213384A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193821A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232543A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213380A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105250277A (zh) * | 2015-11-11 | 2016-01-20 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232546A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213387A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105476990A (zh) * | 2015-11-11 | 2016-04-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287531A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213383A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287534A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232552A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193796A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193801A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287533A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
CN114025844B (zh) * | 2019-03-14 | 2022-07-26 | 卡里科生命科学有限责任公司 | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1492780B1 (en) * | 2002-04-03 | 2011-11-23 | Novartis AG | 5-substituted 1,1-dioxo-¬1,2,5 thiazolidine-3-one derivatives as ptpase 1b inhibitors |
GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
-
2008
- 2008-06-02 AR ARP080102325A patent/AR066820A1/es unknown
- 2008-06-03 EP EP08760391A patent/EP2155704A1/en not_active Withdrawn
- 2008-06-03 CN CN200880018827A patent/CN101687828A/zh active Pending
- 2008-06-03 US US12/602,709 patent/US20100197744A1/en not_active Abandoned
- 2008-06-03 WO PCT/EP2008/056807 patent/WO2008148744A1/en active Application Filing
- 2008-06-03 CL CL2008001612A patent/CL2008001612A1/es unknown
- 2008-06-03 TW TW097120602A patent/TW200911769A/zh unknown
- 2008-06-03 PE PE2008000936A patent/PE20090762A1/es not_active Application Discontinuation
- 2008-06-03 JP JP2010510761A patent/JP2010529075A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2008148744A1 (en) | 2008-12-11 |
JP2010529075A (ja) | 2010-08-26 |
PE20090762A1 (es) | 2009-07-09 |
EP2155704A1 (en) | 2010-02-24 |
TW200911769A (en) | 2009-03-16 |
AR066820A1 (es) | 2009-09-16 |
US20100197744A1 (en) | 2010-08-05 |
CN101687828A (zh) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001612A1 (es) | 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. | |
CL2013001964A1 (es) | Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras. | |
CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
CL2011001094A1 (es) | Compuesto derivados de pirazin-2-iloxi, inhibidores de pde10; composición farmacéutica que comprende a los compuestos; y uso de los compuestos en la preparación de medicamentos para tratar enfermedades, tales como obesidad, diabetes no dependiente de insulina, esquizofernia, bipolaridad, trastorno obsesivo-compulsivo y similares. | |
CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
UY32094A (es) | Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso. | |
CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
CL2008002871A1 (es) | Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad. | |
CL2008001197A1 (es) | Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras. | |
CL2010001496A1 (es) | Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina. | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
CL2008001821A1 (es) | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. | |
CL2013002871A1 (es) | Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
CL2007003733A1 (es) | Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
CL2008000592A1 (es) | Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras. |